TX-MARY-KAY
21.11.2023 18:04:33 CET | Business Wire | Press release
Mary Kay Inc., a global beauty brand and advocate for women’s empowerment, is excited to announce its membership in the Global Shea Alliance (GSA), a non-profit industry association that designs, develops and delivers strategies that drive a competitive and sustainable shea industry worldwide. This new partnership aligns with Mary Kay's commitment to sustainability and its mission to empower women around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231121605161/en/
“This partnership marks a significant step in our journey to promote sustainable beauty practices. By collaborating with the Global Shea Alliance, we aim to further harness the transformative potential of shea in skincare and cosmetics," said Deborah Gibbins, Chief Operating Officer at Mary Kay. (Credit: Mary Kay Inc.).
The GSA's core values are founded on promoting an inclusive value chain, fostering a pre-competitive and business-driven industry by ensuring sustainability and maintaining confidentiality in all transactions with its stakeholders.
“We are absolutely thrilled to join the Global Shea Alliance,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “This partnership marks a significant step in our journey to promote sustainable beauty practices. By collaborating with the GSA, we aim to further harness the transformative potential of shea in skincare and cosmetics.”
Mamatou Djaffo, President of the Global Shea Alliance, expressed her enthusiasm about the new partnership. “We extend a heartfelt welcome to Mary Kay Inc,” said Mamatou Djaffo. “Their stellar reputation as champions of corporate social responsibility and sustainability perfectly aligns with our mission. We are thrilled at the prospect of collaborating with Mary Kay to drive substantial positive change within the cosmetics industry. Together, we aim to establish new industry standards for social and environmental responsibility, transcending beauty to empower individuals, promote sustainability, and foster a more resilient future for the millions of women who depend on shea.”
This exciting partnership between Mary Kay Inc. and the Global Shea Alliance in the upcoming year will spearhead initiatives aimed at enhancing the economic well-being of shea collectors and processors, as well as undertaking crucial efforts to restore degraded parklands in West Africa.
Earlier this month, Mary Kay hosted Aaron Adu, GSA Managing Director, and Olawunmi Osholake, GSA Deputy Managing Director, at its manufacturing facility, the Richard R. Rogers (R3) Manufacturing / R&D Center in Lewisville, Texas, U.S.A. for a site visit followed by a meeting exploring synergies and engagement opportunities.
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram and LinkedIn, or follow us on X (formerly known as Twitter).
About Global Shea Alliance
The GSA is a non-profit industry association with 919 members from 39 countries including women collectors and processors, brands and retailers, ingredient suppliers, civil society, research institutions and policymakers. Through public-private partnerships, the GSA promotes industry sustainability, quality practices and standards and demand for shea in food and cosmetics. For more information, please visit https://globalshea.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231121605161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom